Intermittent Bisphosphonate Therapy in Postmenopausal Osteoporosis: Progress to Date

Authors: Reginster, Jean-Yves1; Malaise, Olivier1; Neuprez, Audrey1; Jouret, Victor-Emmanuel1; Close, Pierre2

Source: Drugs & Aging, Volume 24, Number 5, 2007 , pp. 351-359(9)

Publisher: Adis International

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content

Abstract:

Bisphosphonates are the most widely prescribed drugs in osteoporosis today. They have unequivocally shown their ability to reduce fracture rate at the spine (alendronic acid, risedronic acid, ibandronic acid) and at the hip (alendronic acid and risedronic acid). However, their dosage and administration procedures and the adverse reactions induced by their oral intake are responsible for low adherence. Therefore, intermittent regimens have been developed. Weekly alendronic acid and risedronic acid provide similar benefits, in terms of bone mineral density (BMD) and changes in biochemical markers, as those seen with their daily formulations. Ibandronic acid has been shown to reduce vertebral fractures when given intermittently. Ibandronic acid given orally monthly and intravenously every 2 or 3 months provides increases in BMD similar to the daily formulation. Yearly intravenous infusions of zoledronic acid are currently being evaluated for their ability to reduce fractures. If the efficacy and safety of bisphosphonates given at administration intervals longer than weekly are confirmed, this might significantly improve patient adherence and long-term outcomes of bisphosphonate treatment in postmenopausal osteoporosis.

Keywords: Alendronic acid; Ibandronic acid; Postmenopausal osteoporosis; Risedronic acid; Zoledronic acid

Document Type: Leading article

Affiliations: 1: 1 Department of Public Health, Epidemiology and Health Economics, CHU Sart Tilman, University of Liège, Liège, Belgium 2: 2 Department of Physical Medicine and Rehabilitation, CHU Sart Tilman, University of Liège, Liège, Belgium

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$62.95 plus tax      Refund Policy

 

OR

Back to top

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages.
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A